FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION

DATE: April 28, 2005 MATTER NUMBER: 10407396

OMRE:056US

RECIPIENT:	FAX NO.:	PHONE NO.:
D. Margaret Seaman, Examiner GAU 1625 Patent and Trademark Office	703/872-9306	

FROM: Martha A. Robinson USER ID: MR10031 FLOOR: 20

PHONE: (512) 536-5616 FAX: (512) 536-4598

RE: RESUBMISSION OF IDS AND FORM PTO-1449

NUMBER OF PAGES WITH COVER PAGE: 16 Originals Will Not Follow

Message:

U.S. Application No. 09/506,988 entitled "PROTEASE INHIBITORS THAT OVERCOME DRUG RESISTANCE" by Tang and Ghosh.

Thank you for your attention to this matter.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL MARTHA ROBINSON AT 512/536-5616 AS SOON AS POSSIBLE.

FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

April 28, 2005

CERTIFICATE OF FACSIMILE TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, Washington, D.C. 20231, Attn: Examiner D. Margaret M. Seaman, GAU 1625, facsimile number (703)872-9306 on the date below:

April 28, 2005 — Steven L. Highlander
Date

D. Margaret Seaman, Examiner
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 09/506,988 entitled "PROTEASE INHIBITORS THAT OVERCOME DRUG RESISTANCE" – Jordan J.N. Tang and Arun K. Ghosh*
Our reference: OMRF:056US
Client reference:

Dear Examiner Seaman:

After reviewing each of the Office Actions and the Notice of Allowability, it has come to our attention that the Information Disclosure Statement, Form PTO-1449 and 57 references submitted on July 25, 2000, were apparently never signed off by an Examiner.

For your convenience we have enclosed a copy of a Supplemental Information Disclosure Statement and Form PTO-1449 that was filed with the Patent and Trademark Office (PTO) on July 25, 2000. Also enclosed is a copy of PTO stamped postcard indicating the documents submitted. The copies of the references previously submitted have not been enclosed. Please let us know if you would like us to resubmit those as well.

Please review and approve this Supplemental Information Disclosure Statement. If you need additional information, please let us know.

Thank you for your assistance in this matter.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/mar
Encl: as noted
2552920v1.1

The "Received" stamp of the Patent Office imprinted hereon acknowledges the filing of:

Applicant(s): Jordan J.N. Tang and Arun K. Ghosh

Serial & Docket Nos.: 09/506,988 OMRF 176

Filed: February 18, 2000

Papers Submitted:



Information Disclosure Statement, six (6) pages of Form PTO-1449; and copies of forty-seven (47) documents cited therein.

Date: July 25, 2000 Client/Matter No.: 20487/244

By: Patrea L. Pabst, Reg. No. 31,284



Patrea L. Pabst, Esq.
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450

30303-3449 13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jordan J.N. Tang and Arun K. Ghosh

Serial No.: 09/506,988 Art Unit:

Filed: February 18, 2000 Examiner: Not Yet Assigned

For: *PROTEASE INHIBITORS THAT OVERCOME DRUG RESISTANCE*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including six (6) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 01-2507.

Publications

BALDWIN, et al., "Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase," *Nat. Struct. Biol.* 2(3):244-9 (1995).

BOGER, "Renin Inhibitors. Design of Angiotensinogen Transition-state Analogs Containing Statine:Conformationally restricted inhibitors and a model for the bound conformation of renin substrate," in Aspartic Proteinases and Their Inhibitors, (Kostka, V., ed.), pp. 401-420, Walter de Gruyter:N.Y., 1985.

CARPENTER, et al., "Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel," *JAMA* 280(1):78-86 (1998).

U.S.S.N.: 09/506,988
Filed: February 18, 2000
INFORMATION DISCLOSURE STATEMENT

CARROLL, et al. "Identification of potent inhibitors of *Plasmodium falciparum* plasmepsin II from an encoded statine combinatorial library," *Bioorg. Med. Chem. Lett.* 8(17):2315-20 (1998).

CARROLL, et al., "Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D," *Bioorg. Med. Chem. Lett.* 8(22):3203-6 (1998).

CHEN, et al., "Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials," *J. Biol. Chem.* 270(37):21433-6 (1995).

COFFIN, "HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy," *Science* 267(5197):483-9 (1995).

CONDRA, et al., "Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor," *J. Virol.* 70(12):8270-6 (1996).

CONDRA, et al., "*In vivo* emergence of HIV-1 variants resistant to multiple protease inhibitors," *Nature* 374(6522):569-71 (1995).

CRAIG, et al., "Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase," *Antiviral Res.* 16(4):295-305 (1991).

DEBOUCK & METCALF, "Human Immunodeficiency Virus Protease: A target for AIDS therapy," *Drug Devel. Res.* 21:1-17 (1990).

DEBOUCK, et al., "Human immunodeficiency virus protease expressed in *Escherichia coli* exhibits autoprocessing and specific maturation of the gag precursor," *Proc. Natl. Acad. Sci. USA* 84:8903-8907 (1987).

DORSEY, et al., "L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor," *J. Med. Chem.* 37(21):3443-51 (1994).

DUNN, et al., "Subsite preferences of retroviral proteinases," *Methods Enzymol.* 241:254-178 (1994).

ERMOLIEFF, et al., "Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance *in Vivo*," *Biochemistry* 36(40):12364-70 (1997).

GHOSH, et al., "An efficient synthesis of hydroxyethylene dipeptide isosteres: The core unit of potent HIV-1 protease inhibitors," *J. Org. Chem.* 56:6500-3 (1991)

GHOSH, et al., "3-tetrahydrofuran and pyran urethanes as high-affinity P_2-ligands for HIV-1 protease inhibitors," *J. Med. Chem.* 36:292-94 (1993).

GRAVES, "Human immunodeficiency virus proteinase: now, then, what's next?" *Adv Exp Med Biol.* 306:395-405 (1991).

GULNIK, et al., "Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure," *Biochemistry* 34(29):9282-7 (1995).

HO, et al., "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," *Nature* 373(6510):123-6 (1995).

HONG, et al., "Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases," *Biochemistry* 35:123-126 (1996).

HONG, et al., "Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant," *Protein Sci.* 7(2):300-5 (1998).

HOOVER, et al., "Discovery of inhibitors of human renin with high oral bioavailability," *Adv Exp Med Biol.* 362:167-80 (1995).

IDO, et al., "Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S," *J. Biol. Chem.* 266(36):24359-66 (1991).

JACOBSEN, et al., "Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959," *Virology* 206(1):527-34 (1995).

JACOBSEN, et al., "In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies," *J. Infect. Dis.* 173(6):1379-87 (1996).

KEMPF, et al., "ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans," *Proc. Natl. Acad. Sci. USA.* 92(7):2484-8 (1995).

KOHL, et al., "Active human immunodeficiency virus protease is required for viral infectivity," *Proc. Natl. Acad. Sci. USA* 85(13):4686-90 (1988).

DUNN, et al., "Subsite Preferences of Retroviral Proteinases" *Methods in Enzymology* 241:254-278 (1994).

LAPATTO, et al., "X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes," *Nature* 342(6247):299-302 (1989).

LIN, et al., "Effect of point mutations on the kinetics and the inhibition of human immunodeficiency type 1 protease: Relationship to drug resistance," *Biochemistry* 34:1143-1152 (1995).

MAJER, et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," *Protein Sci.* 6(7):1458-66 (1997).

MARCINISZYN, et al., "Mode of inhibition of acid proteases by pepstatin," *J. Biol. Chem.* 251(22):7088-94 (1976).

MELLORS, "Closing in on human immunodeficiency virus-1," *Nat. Med.* 2(3):274-5 (1996).

MOLLA, et al., "Ordered accumulation of mutations in HIV protease confers resistance to ritonavir," *Nat. Med.* 2(7):760-6 (1996).

MULICHAK & WATENPAUGH, "The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors," *J. Biol. Chem.* 268(18):13103-9 (1993).

NAVIA, et al., "Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1," *Nature* 337(6208):615-20 (1989).

PATICK, et al., "Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease," *Antimicrob. Agents Chemother.* 40(2):292-7 (1996).

PENG, et al., "Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity," *J. Virol.* 63(6):2550-6 (1989).

POORMAN, et al., "A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base," *J. Biol. Chem.* 266(22):14554-61 (1991).

RIDKY & LEIS, "Development of drug resistance to HIV-1 protease inhibitors," *J. Biol. Chem.* 270(50):29621-3 (1995).

RIDKY, et al., "Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites," *J. Biol. Chem.* 271:4709-4717 (1996).

ROCHEFORT, "Biological and clinical significance of cathepsin D in breast cancer," *Semin. Cancer Biol.* 1(2):153-60 (1990).

ROSE, et al., "Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors," *Proc. Natl. Acad. Sci. USA* 93(4):1648-53 (1996).

SCHNEIDER & KENT, "Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease," *Cell* 54(3):363-8 (1988).

SIMAN, et al., "Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments," *J. Biol. Chem.* 268(22):16602-9 (1993).

SZELKE, "Chemistry of Renin Inhibitors," in, Aspartic Proteinases and Their Inhibitors, (Kostka, ed.), pp. 421-441, (Walter de Gruyter:N.Y., 1985).

TANG & HARTSUCK, "A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases," *FEBS Lett.* 367(2):112-6 (1995).

TOH, et al., "Is the AIDS virus recombinant?" *Nature* 316(6023):21-2 (1985).

TOMASSELLI, et al., "The complexities of AIDS: An assessment of the HIV protease as a therapeutic target," *Chimicaoggi-Chemistry Today* 9:6-27 (1991).

TONG, et al., "Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures," *Proc. Natl. Acad. Sci. USA* 90(18):8387-91 (1993).

TOWLER, et al., "Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?" *Biochemistry* 37(49):17137-44 (1998).

VACCA, "Design of Tight-Binding Human Immunodeficiency Virus Type 1 Protease Inhibitors," *Methods in Enzymology* 241:311-334 (1994).

WEI, et al., "Viral dynamics in human immunodeficiency virus type 1 infection," *Nature* 373(6510):117-22 (1995).

WEISS, et al., RNA Tumor Viruses, Cold Spring Harbor:NY, 1984.

WLODAWER & ERICKSON, "Structure-based inhibitors of HIV-1 protease," *Annu. Rev. Biochem.* 62:543-85 (1993).

WLODAWER, et al., "Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease," *Science* 245(4918):616-21 (1989).

U.S.S.N.: 09/506,988
Filed: February 18, 2000
INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Robert A. Hodges
Reg. No. 41,074

Dated: July 25, 2000

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8796
(404) 873-8797 (fax)

U.S.S.N.: 09/506,988
Filed: February 18, 2000
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: July 25, 2000

Julie A. Tennyson

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-00)
Approved for use through 10/31/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/506,988
Filing Date	February 18, 2000
First Named Inventor	Jordan J.N. Tang
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	OMRF 176

Sheet 1 of 6

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		BALDWIN, et al., "Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase," *Nat. Struct. Biol.* 2(3):244-9 (1995).	
		BOGER, "Renin Inhibitors. Design of Angiotensinogen Transition-state Analogs Containing Statine:Conformationally restricted inhibitors and a model for the bound conformation of renin substrate," in Aspartic Proteinases and Their Inhibitors, (Kostka, V., ed.), pp. 401-420, Walter de Gruyter:N.Y., 1985.	
		CARPENTER, et al., "Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel," *JAMA* 280(1):78-86 (1998).	
		CARROLL, et al. "Identification of potent inhibitors of *Plasmodium falciparum* plasmepsin II from an encoded statine combinatorial library," *Bioorg. Med. Chem. Lett.* 8(17):2315-20 (1998).	
		CARROLL, et al., "Evaluation of a structure based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D," *Bioorg. Med. Chem. Lett.* 8(22):3203-6 (1998).	
		CHEN, et al., "Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials," *J. Biol. Chem.* 270(37):21433-6 (1995).	
		COFFIN, "HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy," *Science* 267(5197):483-9 (1995).	
		CONDRA, et al., "Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor," *J. Virol.* 70(12):8270-6 (1996).	
		CONDRA, et al., "*In vivo* emergence of HIV-1 variants resistant to multiple protease inhibitors," *Nature* 374(6522):569-71 (1995).	
		CRAIG, et al., "Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase," *Antiviral Res.* 16(4):295-305 (1991).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Complete If Known	
Application Number	09/506,988
Filing Date	February 18, 2000
First Named Inventor	Jordan J.N. Tang
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	OMRF 176

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
		DEBOUCK & METCALF, "Human Immunodeficiency Virus Protease: A target for AIDS therapy," *Drug Devel. Res.* 21:1-17 (1990).	
		DEBOUCK, et al., "Human immunodeficiency virus protease expressed in *Escherichia coli* exhibits autoprocessing and specific maturation of the gag precursor," *Proc. Natl. Acad. Sci. USA* 84:8903-8907 (1987).	
		DORSEY, et al., "L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor," *J. Med. Chem.* 37(21):3443-51 (1994).	
		DUNN, et al., "Subsite preferences of retroviral proteinases," *Methods Enzymol.* 241:254-178 (1994)	
		ERMOLIEFF, et al., "Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance *in Vivo*," *Biochemistry* 36(40):12364-70 (1997).	
		GHOSH, et al., "3-tetrahydrofuran and pyran urethanes as high-affinity P_2-ligands for HIV-1 protease inhibitors," *J. Med. Chem.* 36:292-94 (1993).	
		GHOSH, et al., "An efficient synthesis of hydroxyethylene dipeptide isosteres: The core unit of potent HIV-1 protease inhibitors," *J. Org. Chem.* 56:6500-3 (1991)	
		GRAVES, "Human immunodeficiency virus proteinase: now, then, what's next?" *Adv Exp Med Biol.* 306:395-405 (1991).	
		GULNIK, et al., "Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure," *Biochemistry* 34(29):9282-7 (1995).	
		HO, et al., "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," *Nature* 373(6510):123-6 (1995).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/506,988
Filing Date	February 18, 2000
First Named Inventor	Jordan J.N. Tang
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	OMRF 176

Sheet	3	of	6

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		DUNN, et al., "Subsite Preferences of Retroviral Proteinases" *Methods in Enzymology* 241:254-278 (1994).	
		HONG, et al., "Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant." *Protein Sci.* 7(2):300-5 (1998).	
		HONG, et al., "Crystal structures of complexes of a peptidic inhibitor with wild type and two mutant HIV-1 proteases," *Biochemistry* 35:123-126 (1996).	
		HOOVER, et al., "Discovery of inhibitors of human renin with high oral bioavailability," *Adv Exp Med Biol.* 362:167-80 (1995).	
		IDO, et al., "Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S," *J. Biol. Chem.* 266(36):24359-66 (1991).	
		JACOBSEN, et al., "Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959," *Virology* 206(1):527-34 (1995).	
		JACOBSEN, et al., "In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies," *J. Infect. Dis.* 173(6):1379-87 (1996).	
		KEMPF, et al., "ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans," *Proc. Natl. Acad. Sci. U S A.* 92(7):2484-8 (1995).	
		KOHL, et al., "Active human immunodeficiency virus protease is required for viral infectivity," *Proc. Natl. Acad. Sci. USA* 85(13):4686-90 (1988).	
		LAPATTO, et al., "X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes," *Nature* 342(6247):299-302 (1989).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [ ]

PTO/SB/08A (10-00)
Approved for use through 10/31/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	09/506,988
Filing Date	February 18, 2000
First Named Inventor	Jordan J.N. Tang
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	OMRF 176

Sheet 4 of 6

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
		LIN, et al., "Effect of point mutations on the kinetics and the inhibition of human immunodeficiency type 1 protease: Relationship to drug resistance," *Biochemistry* 34:1143-1152 (1995).	
		MAJER, et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," *Protein Sci.* 6(7):1458-66 (1997).	
		MARCINISZYN, et al., "Mode of inhibition of acid proteases by pepstatin," *J. Biol. Chem.* 251(22):7088-94 (1976).	
		MELLORS, "Closing in on human immunodeficiency virus-1," *Nat. Med.* 2(3):274-5 (1996).	
		MOLLA, et al., "Ordered accumulation of mutations in HIV protease confers resistance to ritonavir," *Nat. Med.* 2(7):760-6 (1996).	
		MULICHAK & WATENPAUGH, "The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptide transition state analog inhibitors," *J. Biol. Chem.* 268(18):13103-9 (1993).	
		NAVIA, et al., "Three dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1," *Nature* 337(6208):615-20 (1989).	
		PATICK, et al., "Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease," *Antimicrob. Agents Chemother.* 40(2):292-7 (1996).	
		PENG, et al., "Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity," *J. Virol.* 63(6):2550-6 (1989).	
		POORMAN, et al., "A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base," *J. Biol. Chem.* 266(27):14554-61 (1991).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-00)
Approved for use through 10/31/02. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known	
Application Number	09/506,988
Filing Date	February 18, 2000
First Named Inventor	Jordan J.N. Tang
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	OMRF 176

Sheet 5 of 6

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
		RIDKY & LEIS, "Development of drug resistance to HIV-1 protease inhibitors," *J. Biol. Chem.* 270(50):29621-3 (1995).	
		RIDKY, et al., "Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites," *J. Biol. Chem.* 271:4709-4717 (1996).	
		ROCHEFORT, "Biological and clinical significance of cathepsin D in breast cancer," *Semin. Cancer Biol.* 1(2):153-60 (1990).	
		ROSE, et al., "Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors," *Proc. Natl. Acad. Sci. USA* 93(4):1648-53 (1996).	
		SCHNEIDER & KENT, "Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease," *Cell* 54(3):363-8 (1988).	
		SIMAN, et al., "Processing of the beta amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments," *J. Biol. Chem.* 268(22):16602-9 (1993).	
		SZELKE, "Chemistry of Renin Inhibitors," in, Aspartic Proteinases and Their Inhibitors, (Kostka, ed.), pp. 421-441, (Walter de Gruyter:N.Y., 1985).	
		TANG & HARTSUCK, "A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases," *FEBS Lett.* 367(2):112-6 (1995).	
		TOH, et al., "Is the AIDS virus recombinant?" *Nature* 316(6023):21-2 (1985).	
		TOMASSELLI, et al., "The complexities of AIDS: An assessment of the HIV protease as a therapeutic target," *Chimicaoggi Chemistry Today* 9:6-27 (1991).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-00)
Approved for use through 10/31/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known	
Application Number	09/506,988
Filing Date	February 18, 2000
First Named Inventor	Jordan J.N. Tang
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	OMRF 176

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		TONG, et al., "Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures," *Proc. Natl. Acad. Sci. USA* 90(18):8387-91 (1993).	
		TOWLER, et al., "Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?" *Biochemistry* 37(49):17137-44 (1998).	
		VACCA, "Design of Tight-Binding Human Immunodeficiency Virus Type 1 Protease Inhibitors," *Methods in Enzymology* 241:311-334 (1994).	
		WEI, et al., "Viral dynamics in human immunodeficiency virus type 1 infection," *Nature* 373(6510):117-22 (1995).	
		WEISS, et al., RNA Tumor Viruses, Cold Spring Harbor:NY, 1984.	
		WLODAWER & ERICKSON, "Structure-based inhibitors of HIV-1 protease," *Annu. Rev. Biochem.* 62:543-85 (1993).	
		WLODAWER, et al., "Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease," *Science* 245(4918):616-21 (1989).	

Examiner's Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.